Pharma

Sun Pharmaceutical (SUNPHARMA) News:

is running awareness campaigns and continues product launches; company press releases show ongoing commercial activity. What it means: Large Indian pharma companies diversify via product launches and tie-ups — stable cash flows but R&D/regulatory outcomes create event risk. For beginners: pharma is defensive in slowdowns but has binary regulatory outcomes. Risks: Drug approvals, patent/clash issues, pricing pressure in global markets. Tip: Track approval pipelines and therapy area margins; allocate small portion of defensive allocation to large pharma.